CA2047363C - Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs - Google Patents

Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs Download PDF

Info

Publication number: CA2047363C
Authority: CA; Canada
Prior art keywords: acting regulatory; host cell; cis; construct; sequence
Prior art date: 1989-01-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002047363A

Other languages

English (en)

Other versions

CA2047363A1 (fr

Inventor

Mark A. Goldsmith

Robert O. Ralston

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-23

Filing date

1991-07-18

Publication date

2001-07-03

1990-01-22 Priority to EP90902891A priority Critical patent/EP0454781B1/fr

1990-01-22 Priority to JP2503423A priority patent/JP2752788B2/ja

1990-01-22 Priority to EP97113730A priority patent/EP0832980B1/fr

1990-01-22 Priority to PCT/US1990/000445 priority patent/WO1990007936A1/fr

1991-07-18 Application filed by Chiron Corp filed Critical Chiron Corp

1991-07-18 Priority to CA002047363A priority patent/CA2047363C/fr

1993-01-19 Publication of CA2047363A1 publication Critical patent/CA2047363A1/fr

2001-07-03 Application granted granted Critical

2001-07-03 Publication of CA2047363C publication Critical patent/CA2047363C/fr

2011-07-18 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

208000015181 infectious disease Diseases 0.000 title claims abstract description 61
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 52
230000003463 hyperproliferative effect Effects 0.000 title claims description 36
238000002560 therapeutic procedure Methods 0.000 title description 6
108090000623 proteins and genes Proteins 0.000 claims abstract description 197
230000001105 regulatory effect Effects 0.000 claims abstract description 156
239000012636 effector Substances 0.000 claims abstract description 93
230000014509 gene expression Effects 0.000 claims abstract description 88
108091033319 polynucleotide Proteins 0.000 claims abstract description 57
102000040430 polynucleotide Human genes 0.000 claims abstract description 57
239000002157 polynucleotide Substances 0.000 claims abstract description 57
238000013518 transcription Methods 0.000 claims abstract description 26
230000035897 transcription Effects 0.000 claims abstract description 26
230000006378 damage Effects 0.000 claims abstract description 24
230000004224 protection Effects 0.000 claims abstract description 12
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims abstract description 11
239000013598 vector Substances 0.000 claims description 114
239000012678 infectious agent Substances 0.000 claims description 66
238000000034 method Methods 0.000 claims description 46
208000035475 disorder Diseases 0.000 claims description 39
208000031886 HIV Infections Diseases 0.000 claims description 36
239000013612 plasmid Substances 0.000 claims description 35
230000001177 retroviral effect Effects 0.000 claims description 35
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 30
101710149951 Protein Tat Proteins 0.000 claims description 27
241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 26
230000027455 binding Effects 0.000 claims description 26
238000009739 binding Methods 0.000 claims description 26
239000003550 marker Substances 0.000 claims description 25
102000004127 Cytokines Human genes 0.000 claims description 20
108090000695 Cytokines Proteins 0.000 claims description 20
102000004190 Enzymes Human genes 0.000 claims description 20
108090000790 Enzymes Proteins 0.000 claims description 20
230000010076 replication Effects 0.000 claims description 16
102000006382 Ribonucleases Human genes 0.000 claims description 15
108010083644 Ribonucleases Proteins 0.000 claims description 15
108091092562 ribozyme Proteins 0.000 claims description 15
108090000994 Catalytic RNA Proteins 0.000 claims description 14
102000053642 Catalytic RNA Human genes 0.000 claims description 14
239000003112 inhibitor Substances 0.000 claims description 14
238000012423 maintenance Methods 0.000 claims description 14
229940121672 Glycosylation inhibitor Drugs 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 13
102000004169 proteins and genes Human genes 0.000 claims description 13
102000014150 Interferons Human genes 0.000 claims description 12
108010050904 Interferons Proteins 0.000 claims description 12
201000010099 disease Diseases 0.000 claims description 11
238000009877 rendering Methods 0.000 claims description 11
229940079322 interferon Drugs 0.000 claims description 10
239000003242 anti bacterial agent Substances 0.000 claims description 9
230000012010 growth Effects 0.000 claims description 7
239000002502 liposome Substances 0.000 claims description 7
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 7
229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
102000003390 tumor necrosis factor Human genes 0.000 claims description 5
241000701161 unidentified adenovirus Species 0.000 claims description 5
241000702421 Dependoparvovirus Species 0.000 claims description 4
108700007698 Genetic Terminator Regions Proteins 0.000 claims description 4
102000008070 Interferon-gamma Human genes 0.000 claims description 4
108010074328 Interferon-gamma Proteins 0.000 claims description 4
108010002350 Interleukin-2 Proteins 0.000 claims description 4
102000000588 Interleukin-2 Human genes 0.000 claims description 4
206010046865 Vaccinia virus infection Diseases 0.000 claims description 4
230000003115 biocidal effect Effects 0.000 claims description 4
229940044627 gamma-interferon Drugs 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
208000007089 vaccinia Diseases 0.000 claims description 4
239000013603 viral vector Substances 0.000 claims description 4
108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 3
230000013595 glycosylation Effects 0.000 claims description 3
238000006206 glycosylation reaction Methods 0.000 claims description 3
229940047124 interferons Drugs 0.000 claims description 3
230000000813 microbial effect Effects 0.000 claims description 3
230000001131 transforming effect Effects 0.000 claims description 3
102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 2
102000018386 EGF Family of Proteins Human genes 0.000 claims description 2
108010066486 EGF Family of Proteins Proteins 0.000 claims description 2
108010063738 Interleukins Proteins 0.000 claims description 2
102000015696 Interleukins Human genes 0.000 claims description 2
102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
229940047120 colony stimulating factors Drugs 0.000 claims description 2
229940047122 interleukins Drugs 0.000 claims description 2
229940002612 prodrug Drugs 0.000 claims description 2
239000000651 prodrug Substances 0.000 claims description 2
102000003886 Glycoproteins Human genes 0.000 claims 3
108090000288 Glycoproteins Proteins 0.000 claims 3
239000003795 chemical substances by application Substances 0.000 abstract description 16
238000011282 treatment Methods 0.000 abstract description 15
229960004150 aciclovir Drugs 0.000 abstract description 12
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 abstract description 12
108020004440 Thymidine kinase Proteins 0.000 abstract description 10
102000006601 Thymidine Kinase Human genes 0.000 abstract description 9
108010039491 Ricin Proteins 0.000 abstract description 7
108091023040 Transcription factor Proteins 0.000 abstract description 6
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 abstract description 6
229960002963 ganciclovir Drugs 0.000 abstract description 5
241000700588 Human alphaherpesvirus 1 Species 0.000 abstract description 4
230000030833 cell death Effects 0.000 abstract description 4
239000005546 dideoxynucleotide Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 220
241000700584 Simplexvirus Species 0.000 description 55
241000725303 Human immunodeficiency virus Species 0.000 description 41
241000700605 Viruses Species 0.000 description 31
230000003612 virological effect Effects 0.000 description 26
239000000047 product Substances 0.000 description 25
238000004806 packaging method and process Methods 0.000 description 22
108020004414 DNA Proteins 0.000 description 18
101150071065 Ddn gene Proteins 0.000 description 18
108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
210000001744 T-lymphocyte Anatomy 0.000 description 17
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 17
239000003623 enhancer Substances 0.000 description 15
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 13
241001430294 unidentified retrovirus Species 0.000 description 13
241000713869 Moloney murine leukemia virus Species 0.000 description 12
101150003725 TK gene Proteins 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 11
229930193140 Neomycin Natural products 0.000 description 10
230000000694 effects Effects 0.000 description 10
229960004927 neomycin Drugs 0.000 description 10
230000008488 polyadenylation Effects 0.000 description 10
108091026890 Coding region Proteins 0.000 description 9
206010028980 Neoplasm Diseases 0.000 description 9
230000001413 cellular effect Effects 0.000 description 9
239000012634 fragment Substances 0.000 description 9
108020005544 Antisense RNA Proteins 0.000 description 8
208000037357 HIV infectious disease Diseases 0.000 description 8
108010011356 Nucleoside phosphotransferase Proteins 0.000 description 8
239000003443 antiviral agent Substances 0.000 description 8
230000001472 cytotoxic effect Effects 0.000 description 8
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 8
230000002458 infectious effect Effects 0.000 description 8
230000010354 integration Effects 0.000 description 8
210000002540 macrophage Anatomy 0.000 description 8
238000001890 transfection Methods 0.000 description 8
108010067390 Viral Proteins Proteins 0.000 description 7
238000001994 activation Methods 0.000 description 7
210000002798 bone marrow cell Anatomy 0.000 description 7
238000010276 construction Methods 0.000 description 7
231100000433 cytotoxic Toxicity 0.000 description 7
239000003814 drug Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
238000010561 standard procedure Methods 0.000 description 7
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 6
108010033040 Histones Proteins 0.000 description 6
241000598436 Human T-cell lymphotropic virus Species 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 6
230000004913 activation Effects 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
239000002609 medium Substances 0.000 description 6
102000037983 regulatory factors Human genes 0.000 description 6
108091008025 regulatory factors Proteins 0.000 description 6
241000894006 Bacteria Species 0.000 description 5
241000701022 Cytomegalovirus Species 0.000 description 5
102000001253 Protein Kinase Human genes 0.000 description 5
108700008625 Reporter Genes Proteins 0.000 description 5
230000000840 anti-viral effect Effects 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
238000003556 assay Methods 0.000 description 5
210000001185 bone marrow Anatomy 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
238000010367 cloning Methods 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 5
210000003958 hematopoietic stem cell Anatomy 0.000 description 5
210000000987 immune system Anatomy 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
229910052754 neon Inorganic materials 0.000 description 5
230000001566 pro-viral effect Effects 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 4
108010041397 CD4 Antigens Proteins 0.000 description 4
108090000157 Metallothionein Proteins 0.000 description 4
102000003792 Metallothionein Human genes 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000002950 deficient Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000006801 homologous recombination Effects 0.000 description 4
238000002744 homologous recombination Methods 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
244000045947 parasite Species 0.000 description 4
230000026731 phosphorylation Effects 0.000 description 4
238000006366 phosphorylation reaction Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
230000008685 targeting Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
230000014616 translation Effects 0.000 description 4
239000001226 triphosphate Substances 0.000 description 4
235000011178 triphosphate Nutrition 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
241000233866 Fungi Species 0.000 description 3
241000711549 Hepacivirus C Species 0.000 description 3
229920000209 Hexadimethrine bromide Polymers 0.000 description 3
241000701024 Human betaherpesvirus 5 Species 0.000 description 3
241000701806 Human papillomavirus Species 0.000 description 3
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000714177 Murine leukemia virus Species 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
102000016387 Pancreatic elastase Human genes 0.000 description 3
108010067372 Pancreatic elastase Proteins 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
108091036407 Polyadenylation Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
108700005077 Viral Genes Proteins 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 3
108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
210000000234 capsid Anatomy 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
238000010586 diagram Methods 0.000 description 3
231100000676 disease causative agent Toxicity 0.000 description 3
108700004025 env Genes Proteins 0.000 description 3
101150030339 env gene Proteins 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
206010020718 hyperplasia Diseases 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
108091008819 oncoproteins Proteins 0.000 description 3
102000027450 oncoproteins Human genes 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
-1 thus Proteins 0.000 description 3
238000012546 transfer Methods 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
KUOAJOVOKFATQE-UHFFFAOYSA-N 2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethyl dihydrogen phosphate Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOP(O)(O)=O)C=N2 KUOAJOVOKFATQE-UHFFFAOYSA-N 0.000 description 2
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
108091062157 Cis-regulatory element Proteins 0.000 description 2
108050006400 Cyclin Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
101150013359 E7 gene Proteins 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
101710091045 Envelope protein Proteins 0.000 description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
241000713858 Harvey murine sarcoma virus Species 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
241000341655 Human papillomavirus type 16 Species 0.000 description 2
241000222727 Leishmania donovani Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
101710188315 Protein X Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
108091027981 Response element Proteins 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
239000012190 activator Substances 0.000 description 2
201000006966 adult T-cell leukemia Diseases 0.000 description 2
102000018568 alpha-Defensin Human genes 0.000 description 2
108050007802 alpha-defensin Proteins 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
229940077731 carbohydrate nutrients Drugs 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
101150055766 cat gene Proteins 0.000 description 2
230000032823 cell division Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000012258 culturing Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
206010013023 diphtheria Diseases 0.000 description 2
230000002222 downregulating effect Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
108700004026 gag Genes Proteins 0.000 description 2
101150098622 gag gene Proteins 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000002390 hyperplastic effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000000394 mitotic effect Effects 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000001243 protein synthesis Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
241000894007 species Species 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
231100000167 toxic agent Toxicity 0.000 description 2
231100000816 toxic dose Toxicity 0.000 description 2
239000003440 toxic substance Substances 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
230000007486 viral budding Effects 0.000 description 2
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
GONFBOIJNUKKST-UHFFFAOYSA-N 5-ethylsulfanyl-2h-tetrazole Chemical compound CCSC=1N=NNN=1 GONFBOIJNUKKST-UHFFFAOYSA-N 0.000 description 1
SYMHUEFSSMBHJA-UHFFFAOYSA-N 6-methylpurine Chemical compound CC1=NC=NC2=C1NC=N2 SYMHUEFSSMBHJA-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 description 1
MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 1
OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
YCYXHLZRUSJITQ-SRVKXCTJSA-N Arg-Pro-Pro Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 YCYXHLZRUSJITQ-SRVKXCTJSA-N 0.000 description 1
CZIXHXIJJZLYRJ-SRVKXCTJSA-N Asn-Cys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CZIXHXIJJZLYRJ-SRVKXCTJSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
101150054493 BG gene Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
101100298824 Caenorhabditis elegans rpt-1 gene Proteins 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000003712 Complement factor B Human genes 0.000 description 1
108090000056 Complement factor B Proteins 0.000 description 1
QJUDRFBUWAGUSG-SRVKXCTJSA-N Cys-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N QJUDRFBUWAGUSG-SRVKXCTJSA-N 0.000 description 1
KGIHMGPYGXBYJJ-SRVKXCTJSA-N Cys-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CS KGIHMGPYGXBYJJ-SRVKXCTJSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
102400000102 Eosinophil granule major basic protein Human genes 0.000 description 1
101800000338 Eosinophil granule major basic protein Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
208000034951 Genetic Translocation Diseases 0.000 description 1
241000224466 Giardia Species 0.000 description 1
SMLDOQHTOAAFJQ-WDSKDSINSA-N Gln-Gly-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SMLDOQHTOAAFJQ-WDSKDSINSA-N 0.000 description 1
UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 1
SYTFJIQPBRJSOK-NKIYYHGXSA-N Gln-Thr-His Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 SYTFJIQPBRJSOK-NKIYYHGXSA-N 0.000 description 1
FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
IDQKGZWUPVOGPZ-GUBZILKMSA-N His-Cys-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N IDQKGZWUPVOGPZ-GUBZILKMSA-N 0.000 description 1
QCBYAHHNOHBXIH-UWVGGRQHSA-N His-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CN=CN1 QCBYAHHNOHBXIH-UWVGGRQHSA-N 0.000 description 1
101001095043 Homo sapiens Bone marrow proteoglycan Proteins 0.000 description 1
108010071893 Human Immunodeficiency Virus rev Gene Products Proteins 0.000 description 1
241000598171 Human adenovirus sp. Species 0.000 description 1
108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 1
101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 description 1
QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 1
108700002232 Immediate-Early Genes Proteins 0.000 description 1
206010022004 Influenza like illness Diseases 0.000 description 1
102100034353 Integrase Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
241000222722 Leishmania <genus> Species 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
108010030317 Macrophage-1 Antigen Proteins 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
OGAZPKJHHZPYFK-GARJFASQSA-N Met-Glu-Pro Chemical group CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N OGAZPKJHHZPYFK-GARJFASQSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
101100482085 Mus musculus Trim30a gene Proteins 0.000 description 1
BYEIJZFKOAXBBV-ATZCPNFKSA-N N-[(5S)-5-amino-5-carboxypentanoyl]-L-cysteinyl-D-valine Chemical compound CC(C)[C@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)CCC[C@H](N)C(O)=O BYEIJZFKOAXBBV-ATZCPNFKSA-N 0.000 description 1
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 1
DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 1
FYXCBXDAMPEHIQ-FHWLQOOXSA-N Pro-Trp-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CCCCN)C(=O)O FYXCBXDAMPEHIQ-FHWLQOOXSA-N 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241001068295 Replication defective viruses Species 0.000 description 1
101001059240 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Site-specific recombinase Flp Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
BQWCDDAISCPDQV-XHNCKOQMSA-N Ser-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N)C(=O)O BQWCDDAISCPDQV-XHNCKOQMSA-N 0.000 description 1
FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
108091027544 Subgenomic mRNA Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
DDNIHOWRDOXXPF-NGZCFLSTSA-N Val-Asp-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DDNIHOWRDOXXPF-NGZCFLSTSA-N 0.000 description 1
SRWWRLKBEJZFPW-IHRRRGAJSA-N Val-Cys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N SRWWRLKBEJZFPW-IHRRRGAJSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
206010047505 Visceral leishmaniasis Diseases 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
108700025690 abl Genes Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000007488 abnormal function Effects 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000002155 anti-virotic effect Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000009583 bone marrow aspiration Methods 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
230000005889 cellular cytotoxicity Effects 0.000 description 1
230000004098 cellular respiration Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229940015047 chorionic gonadotropin Drugs 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
108010078428 env Gene Products Proteins 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
235000019439 ethyl acetate Nutrition 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
108010092114 histidylphenylalanine Proteins 0.000 description 1
102000056236 human PRG2 Human genes 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000000887 hydrating effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000036046 immunoreaction Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
244000000056 intracellular parasite Species 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000000178 monomer Substances 0.000 description 1
150000004712 monophosphates Chemical class 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000030147 nuclear export Effects 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229940046166 oligodeoxynucleotide Drugs 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
210000004923 pancreatic tissue Anatomy 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000004214 philadelphia chromosome Anatomy 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
108010053725 prolylvaline Proteins 0.000 description 1
229940070376 protein Drugs 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
239000012268 protein inhibitor Substances 0.000 description 1
229940121649 protein inhibitor Drugs 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
239000000007 protein synthesis inhibitor Substances 0.000 description 1
239000002213 purine nucleotide Substances 0.000 description 1
239000002719 pyrimidine nucleotide Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
208000026775 severe diarrhea Diseases 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
101150101054 tar gene Proteins 0.000 description 1
108700004027 tat Genes Proteins 0.000 description 1
101150098170 tat gene Proteins 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000010415 tropism Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
230000007442 viral DNA synthesis Effects 0.000 description 1
230000006648 viral gene expression Effects 0.000 description 1
210000000605 viral structure Anatomy 0.000 description 1
230000006490 viral transcription Effects 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002047363A 1989-01-23 1991-07-18 Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs Expired - Fee Related CA2047363C (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
EP90902891A EP0454781B1 (fr)	1989-01-23	1990-01-22	Cellules de recombinaison pour des therapies d'infections et de troubles hyperproliferatifs et la preparation de ces cellules
JP2503423A JP2752788B2 (ja)	1989-01-23	1990-01-22	感染および過剰増殖障害の為の組換え療法
EP97113730A EP0832980B1 (fr)	1989-01-23	1990-01-22	Thérapie recombinante des infections et désordres hyperprolifératifs
PCT/US1990/000445 WO1990007936A1 (fr)	1989-01-23	1990-01-22	Therapies de recombinaison pour infections et troubles hyperproliferatifs
CA002047363A CA2047363C (fr)	1989-01-23	1991-07-18	Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30063789A	1989-01-23	1989-01-23
CA002047363A CA2047363C (fr)	1989-01-23	1991-07-18	Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs

Publications (2)

Publication Number	Publication Date
CA2047363A1 CA2047363A1 (fr)	1993-01-19
CA2047363C true CA2047363C (fr)	2001-07-03

Family

ID=25674701

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002047363A Expired - Fee Related CA2047363C (fr)	1989-01-23	1991-07-18	Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs

Country Status (1)

Country	Link
CA (1)	CA2047363C (fr)

1991
- 1991-07-18 CA CA002047363A patent/CA2047363C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2047363A1 (fr)	1993-01-19

Legal Events

Date	Code	Title	Description
1992-10-08	EEER	Examination request
2004-07-19	MKLA	Lapsed

Publication	Publication Date	Title
US5861290A (en)	1999-01-19	Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
EP0832980B1 (fr)	2002-06-19	Thérapie recombinante des infections et désordres hyperprolifératifs
EP0415731B1 (fr)	2003-04-02	Substances nouvelles pour la thérapie du cancer
CA2234931C (fr)	2010-01-19	Nouveaux vecteurs d'expression et procedes d'utilisation correspondants
EP0702084B1 (fr)	1999-12-22	Rétrovirus recombinants
Von Rüden et al.	1989	Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA
US6200811B1 (en)	2001-03-13	Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
US20150216948A1 (en)	2015-08-06	Cytochrome p450 suicide gene system
KR20010084913A (ko)	2001-09-07	폴리뉴클레오티드 컨스트럭트 및 그의 용도
WO1997034638A1 (fr)	1997-09-25	Approche anti-sens de l'inhibition des genes
Ragheb et al.	1999	Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev
Dickson	2012	Molecular and cell biology of human gene therapeutics
CA2261987C (fr)	2008-09-30	Vecteurs d'administration d'inhibiteurs de cellules virales et oncogenes
JPH10506007A (ja)	1998-06-16	機能修飾されたｈｓｖ１−ｔｋ
EP0716710B1 (fr)	2000-11-15	Procedes de suppression de la reponse immunitaire par therapie genique
OBARU et al.	1996	Gene therapy for adult T cell leukemia using human immunodeficiency virus vector carrying the thymidine kinase gene of herpes simplex virus type 1
US20040166559A1 (en)	2004-08-26	Vectors for gene therapy
US6953687B1 (en)	2005-10-11	Vectors for delivering viral and oncogenic inhibitors
WO1998003669A9 (fr)	1998-04-23	Vecteurs d'administration d'inhibiteurs de cellules virales et oncogenes
Fujita et al.	1994	Selective inhibition of human T-lymphotropic virus type I-transformed human T-cell growth by a tax-targeted conditionally cytotoxic recombinant retrovirus
EP0977881B1 (fr)	2005-03-02	Expression d'une proteine d'enveloppe modifiee de virus spumeux
US20030091546A1 (en)	2003-05-15	Methods of suppressing immune response by gene therapy
JPWO2009051078A1 (ja)	2011-03-03	治療用遺伝子発現システム
JP2001520017A (ja)	2001-10-30	ヒト免疫不全ウイルス（ｈｉｖ−１）複製の阻害
Tzeng et al.	1996	Genetic Modulation of inducible nitric oxide synthase expression